Unbuzzd closes $771K private placement, eyeing CSE listing
What's the deal? Unbuzzd Wellness, the Vancouver company behind the unbuzzd alcohol-recovery supplement, has closed a non-brokered private placement for US$792K. It issued 5,400,000 common shares at US$0.15 each across two tranches that closed on October 16 and October 21, 2026.
Who's in? Two insiders subscribed for 2,000,000 shares, making their participation a related-party transaction under Canadian securities rules. The company paid US$49.4K in finders' commissions and issued 327,000 compensation warrants exercisable at US$0.15 for 24 months.
Where's it going? Proceeds are earmarked for general working capital, including the company's application to list its shares on the Canadian Securities ExchangeDealroom has a profile for this one. Try Dealroom →, which is still under review. All shares carry a statutory four-month-and-one-day hold period.
Why now? The raise follows the September appointment of a new chief executive officer, whose stated priorities are securing a listing and expanding US marketing. This is an execution-focused round rather than a major growth raise.
What could go wrong? The CSE application remains unapproved, so the path to a public listing is not guaranteed. Unbuzzd also carries a US$953.3K secured loan, with accrued interest, due in December 2027, and a recent restatement widened its reported nine-month 2026 net loss to $358,708.
What's the endgame? Unbuzzd is a non-trading but fully reporting public issuer selling a vitamin, mineral, and herb blend it says helps the body process alcohol faster. It points to a double-blind, randomised, placebo-controlled clinical trial to support its claims.
The signal: For Unbuzzd, this modest capital marks a step up from its prior round, but the real test is execution. Whether US$792K is enough to clear the CSE hurdle and fund a US rollout matters far more than the size of the cheque.
Read more: finanznachrichten.de
Image credit: Generated with Gemini
